<DOC>
	<DOCNO>NCT01025505</DOCNO>
	<brief_summary>This study open-label , multicentric , exploratory , single arm , phase II study adult either 60 year old , unfit intensive chemotherapy allo SCT . The patient treat NILOTINIB , administer orally twice daily , 6 week ( Course A ) follow IMATINIB , administer orally twice daily , 6 week ( Course B ) .The course repeat ( rotate ) total 4 time relapse , interest patient . Prednisone ( P ) administer patient 7-14 day , TKIs , make possible wait result cytogenetic molecular test , evaluate response P alone , hence another 21 day . Intrathecal therapy ( IT ) MTX/AraC/DEX mandatory , monthly , patient without clinical-cytologic evidence meningeal involvement , patient CNS involvement perform twice weekly clearance leukemic cell , hence weekly . IM administer dosage 600 mg daily ( 300 mg twice daily ) Nilotinib dosage 800 mg daily ( 400 mg twice daily ) course . All patient schedule receive least 4 course either drug , total 4 course ( 4 x 6 = 24 week ) . After 4 course , patient either allow continue treatment relapse progression , interest , discontinue treatment receive therapy .</brief_summary>
	<brief_title>Ph+/Bcr-Abl+ ALL Imatinib Nilotinib Rotational Study</brief_title>
	<detailed_description />
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Previously untreated Ph+ ALL 60 year old 18 year old , unfit program intensive therapy allogeneic SCT</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Untreated Ph+ ALL unfit intense therapy allo SCT</keyword>
</DOC>